Neuroplasticity and major depression, the role of modern antidepressant drugs.

  title={Neuroplasticity and major depression, the role of modern antidepressant drugs.},
  author={Gianluca Serafini},
  journal={World journal of psychiatry},
  volume={2 3},
  • G. Serafini
  • Published 22 June 2012
  • Psychology, Biology
  • World journal of psychiatry
The pathophysiology of depression has been traditionally attributed to a chemical imbalance and critical interactions between genetic and environmental risk factors, and antidepressant drugs suggested to act predominantly amplifying monoaminergic neurotransmission. This conceptualization may be currently considered reductive. The current literature about the pathophysiological mechanisms underlying depression, stress-related disorders and antidepressant treatment was examined. In order to… 

Figures from this paper

Neuroplasticity and depression: Rewiring the brain's networks through pharmacological therapy (Review)
The current review aimed to underline the negative effects of depression on neuroplasticity and present the current findings on the effects of antidepressant medication.
From Serotonin to Neuroplasticity: Evolvement of Theories for Major Depressive Disorder
The evidence challenging the monoamine hypothesis is summarized and proposed that the antidepressant efficacy of SSRIs is not derived from elevated monoamine (5-HT, noradrenaline (NE), or dopamine (DA) concentration or monoamine neurotransmission.
Animal models of major depressive disorder and the implications for drug discovery and development
Dividing the core symptoms into easily translatable, evolutionarily conserved phenotypes is an effective way to reevaluate current depression modeling, and novel approaches based on the endophenotype paradigm, cross-species trait genetics and ‘domain interplay concept’ will enhance experimental modeling of depression and antidepressant drug discovery.
A mitochondrial bioenergetic basis of depression
While there is substantial evidence linking mitochondrial bioenergetics and MDD, there are currently no clear mitochondrial phenotypes or biomarkers to use as guides in targeting therapies beyond individuals with MDD and known mitochondrial disorders toward the general population of individuals withMDD.
Neuroinflammation and Mitochondrial Dysfunction Link Social Stress to Depression.
Evidence for neuroinflammation and mitochondrial dysfunction in the pathogenesis of social stress-induced depression are reviewed and discussed in the context of novel therapeutic targets for the treatment of depression.
A role for CRH and HPA Activation in the Regulation of Plasticity Signaling, Neuroinflammation and Emotional/Mnesic Behavior Following Global Cerebral Ischemia in Rats
The purpose of the current thesis is to characterize the effect of pharmacological blockade of CRH signaling at the onset of a global ischemic stroke on emotional and cognitive behaviors, alteration in the neuroendocrine stress system, and markers of neuroplasticity including BDNF.


How antidepressant drugs act: A primer on neuroplasticity as the eventual mediator of antidepressant efficacy
The stress–depression syndrome and the therapeutic and prophylactic efficacy of antidepressant treatments can be explained through a hardwiring analogy because glutamate is an important neurotransmitter.
[Depression and neuroplasticity: implication of serotoninergic systems].
It is demonstrated that agomelatine, a new antidepressant drug having serotonergic and melatonergic properties, can increase proliferation and survival of newly formed hippocampal cells, reinforcing the view that changes in hippocampal neurogenesis might belong to the cellular correlates of mood disorders.
Neurobiological and Clinical Effects of the Antidepressant Tianeptine
The neurobiological properties of tianeptine may provide an explanation not only for its antidepressant activity, but also for its anxiolytic effects in depressed patients and its lack of adverse effects on cognitive function and memory.
Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics.
Evidence from a variety of sources demonstrating regional reductions in central nervous system volume, as well as reductions in the numbers and/or sizes of glia and neurons in discrete brain areas suggests that mood disorders are associated with impairments of structural plasticity and cellular resilience.
Antidepressants and neuroplasticity.
The results suggest that depression maybe associated with a disruption of mechanisms that govern cell survival and neural plasticity in the brain and antidepressants could mediate their effects by increasing neurogenesis and modulating the signaling pathways involved in plasticity and survival.
The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling
These experiments suggest re-establishment of neuronal plasticity (dendritic remodeling and synaptic contacts) in the hippocampus and prefrontal cortex, rather than neurogenesis, as the basis for the restoration of behavioral homeostasis by antidepressants.
Role of neurotrophic factors in depression.